In the rapidly evolving landscape of digital health, a new and unsettling phenomenon has begun to emerge. While the public has become increasingly aware of "AI psychosis" at the individual level—where users develop pathological dependencies on chatbots—a more systemic and perhaps more dangerous version of this delusion is taking root in the boardrooms of the healthcare industry. This corporate AI psychosis, characterized by an irrational belief in the transformative power of unproven technologies, is now colliding with the delicate field of addiction treatment, threatening to prioritize administrative efficiency over clinical efficacy.
n
Main Facts: The Dual Nature of AI Psychosis
n
The term "AI psychosis" originally gained traction to describe the psychological breakdown experienced by individuals who treat Large Language Models (LLMs) as sentient companions. The positive reinforcement loops built into these systems can, in extreme cases, lead to self-harm, criminal behavior, and a detachment from reality. However, as digital rights activist Cory Doctorow recently posited in his Pluralistic newsletter, there is a secondary, institutional form of this psychosis: the "delusional belief" in what AI can realistically achieve for a business.
n
In the context of addiction treatment, this manifests as a mandatory drive to implement AI solutions, often at the behest of high-priced consultants, despite a lack of evidence that these tools improve patient outcomes. A recent "confession" from a retired CEO of a major nonprofit addiction treatment system, published by Better Health Business (BHB), highlights a growing rift between the "top-down" mandates of healthcare executives and the "bottom-up" needs of patients struggling with substance use disorders.
n
The core of the issue lies in three distinct areas:
n
- n
- Investor Delusion: The belief that AI will generate unprecedented profits simply because it is perceived as a "disruptor," regardless of its actual utility.
- Boss Delusion: The conviction that AI can replace skilled human labor or exponentially increase productivity without sacrificing the quality of care.
- Data Fragmentation: The reality that healthcare data remains trapped in competitive silos, rendering the "intelligence" of AI largely toothless.
n
n
n
n
Chronology: From Chatbot Hype to Institutional Mandate
n
To understand how the addiction treatment industry arrived at this crossroads, one must look at the timeline of AI integration over the last several years.
n
2022–2023: The Dawn of Generative AI
n
The release of ChatGPT and subsequent LLMs sparked a global gold rush. In the healthcare sector, early adopters began experimenting with AI for administrative tasks, such as transcribing doctor-patient notes and automating billing codes. During this phase, the technology was viewed as a "supplementary tool."
n
2024–2025: The Rise of the AI Consultant
n
As venture capital flooded the AI space, a new wave of consultancy emerged. These firms began pitching AI not as a tool, but as a "foundational necessity." Addiction treatment centers, many of which operate on thin margins, were told that failing to adopt AI would result in obsolescence. It was during this period that "AI Psychosis" began to shift from the user to the executive.
n
2026: The "Must-Have" Era and the Internal Backlash
n
By mid-2026, the sentiment captured by the retired CEO in the Better Health Business interview became prevalent: "You have to have it if you don’t have it." This period is defined by a frantic push to implement AI systems even when the infrastructure—such as integrated data sets—is missing. The industry is currently seeing a "recycling of solutions," where old problems are rebranded as "AI-solvable," leading to what many veterans call a form of corporate self-harm.
n
Supporting Data: The Mechanics of Delusion and the Silo Problem
n
The argument for corporate AI psychosis is supported by the structural realities of the American healthcare system. Cory Doctorow’s analysis identifies a "bubble exceptionalism" where the normal rules of economics are suspended in favor of AI hype.
n
The Problem of Data Silos
n
For an AI to provide "breakthrough results" in addiction treatment, it requires access to holistic data: medical histories, socioeconomic factors, insurance claims, and longitudinal outcomes. However, the BHB report points out a critical failure:
n
- n
- Insurer Secrecy: Health insurers utilize AI to maximize their own profitability but refuse to share the underlying data with healthcare providers or government agencies.
- Provider Isolation: Clinics often treat patients in a vacuum, lacking access to the very data sets that would allow an AI to make an informed recommendation.
n
n
n
Without this data, an AI is essentially a "stochastic parrot," guessing at solutions based on incomplete information. In addiction treatment, where a wrong guess can lead to a fatal relapse, the stakes of this data-less "intelligence" are uniquely high.
n
The Productivity Paradox
n
Executives suffering from "boss delusion" often believe AI will allow for massive layoffs. However, in behavioral health, the "product" is human connection and empathy—elements that AI cannot replicate. Data suggests that while AI can draft a treatment plan, the actual implementation requires a human clinician who can navigate the nuances of a patient’s emotional state. When organizations cut staff to pay for AI licenses, the quality of care invariably drops, leading to higher turnover and lower recovery rates.
n
Official Responses: Insights from the Front Lines
The "BHB Confessions" series provides a rare, unvarnished look at the internal skepticism within the industry. The retired CEO, a 50-year veteran of behavioral health, expressed profound trouble regarding the current trajectory.
"There are these things that come along that are driven by a lot of the consultants that really don’t play out," the CEO noted. He emphasized that the drive for AI is often a "top-down" imposition that ignores the fundamental mechanics of how addiction treatment is funded and delivered.
According to this executive perspective:
- Budgetary Realities: AI cannot "hallucinate" a budget into existence. Most nonprofit budgets are fully committed to payroll and facility costs. New AI initiatives often require diverting funds away from direct patient care.
- The Source of Innovation: True innovation in addiction treatment has historically come from "passionate people" working on the ground, not from algorithmic efficiency.
- The Efficiency Trap: The CEO warned that the desire to "operate more efficiently" often comes at the expense of the patient experience. In the world of recovery, efficiency is often the enemy of progress, as recovery is a slow, non-linear human process.
While technology companies and some current CEOs defend the shift as a necessary evolution to handle the scale of the opioid crisis, the "confessions" suggest a growing movement of "bottom-up" resistance among clinicians who see AI as a distraction from proven, evidence-based practices.
Implications: The Risks of Corporate Self-Harm
The consequences of AI psychosis in the addiction treatment sector extend far beyond wasted capital. If the industry continues to chase the mirage of algorithmic salvation, several long-term risks emerge:
1. The Erosion of Evidence-Based Care
There is a danger that "what the AI suggests" will begin to carry more weight than "what we know works." If an AI identifies a "cost-effective" treatment path that ignores the human necessity of long-term counseling, organizations may be tempted to follow the algorithm to satisfy board members or investors, leading to a decline in successful long-term recovery.
2. The Devaluation of the Clinician
By treating AI as a replacement for human expertise, the industry risks devaluing the very professionals who are most essential to the recovery process. This could exacerbate the already critical shortage of mental health and addiction counselors, as professionals flee an environment that prioritizes machine logic over clinical intuition.
3. The Bursting of the "Efficiency Bubble"
If, as the retired CEO suggests, AI fails to deliver the promised "breakthroughs" because of data silos and the inherent complexity of addiction, the industry may face a financial crisis. When the "investor delusion" pops, organizations that over-leveraged themselves to implement AI may find themselves without the resources to maintain basic operations.
4. A Call for "Bottom-Up" Technology
The ultimate implication is the need for a paradigm shift. Rather than asking "How can AI make us more profitable?", organizations should be asking "How can technology support the existing relationship between the counselor and the patient?"
The retired CEO’s parting advice to the industry was clear: Build from the bottom up. Put the needs of the person using addiction treatment ahead of the organization’s desire for a digital silver bullet. Until the industry addresses the "psychosis" of its leadership, the true potential of technology will remain buried under a mountain of hype, leaving those most in need of help to navigate a system that is increasingly intelligent, but decreasingly human.
Disclaimer: If you are struggling with thoughts of suicide or self-harm, contact the Crisis and Suicide Lifeline at 9-8-8 or visit 988lifeline.org. Support is available 24/7.
